Retatrutide Side Effects: By System, By Dose, vs Tirzepatide and Semaglutide (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and not FDA-approved as of 2026; its full safety profile is still being established in Phase 3. Do not start, stop, or change treatment based on this. Consult your doctor.

Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon). In its Phase 2 obesity trial, the side effect pattern looked a lot like other incretin drugs, with one twist: a dose-related bump in heart rate. This guide breaks the data down by body system, by dose, and against tirzepatide and semaglutide.

The numbers here come from published trial results. Where Phase 3 data is not yet out, we say so.

One thing to keep front of mind. Retatrutide is not approved. The figures below come mostly from a single Phase 2 trial that ran 48 weeks. They are real, but they are early. The full safety story will not be settled until Phase 3 reads out.

What are retatrutide's most common side effects?

Most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and they were dose-related in the Phase 2 trial. They were mostly mild to moderate and tended to show up during dose escalation.

The drug also produced a dose-related rise in resting heart rate. That cardiovascular signal is the one finding that sets retatrutide apart from the dual and single agonists (Jastreboff et al., NEJM 2023).

Here is the picture by body system, drawn from the Phase 2 trial (NCT04881760).

Body system	What was reported	Notes
Gastrointestinal	Nausea, vomiting, diarrhea, constipation	Most common; dose-related; worst during titration (NEJM 2023)
Cardiovascular / heart rate	Resting heart rate up to ~6.7 bpm higher at 12 mg	Peaked around week 24, then drifted back toward baseline (NEJM 2023)
Injection site	Local reactions (redness, itching)	Reported but uncommon; typical of subcutaneous injectables
Metabolic	Low blood sugar risk mainly when combined with insulin or sulfonylureas	Hypoglycemia is a class consideration (Wegovy label, FDA 2023)

Most people did not stop treatment. But discontinuation due to side effects did climb with dose, which we cover below (NEJM 2023).

A quick word on what "common" means here. Gut symptoms were by far the most frequent. The heart rate change was consistent but modest in size. Injection-site and metabolic effects were less common and broadly in line with what the rest of the class shows.

Severity matters as much as frequency. Most gut symptoms in the trial were rated mild or moderate. They tended to fade after the dose stabilized, which is the usual pattern for incretin drugs (Jastreboff et al., PubMed 2023).

How do side effects change by dose?

Side effects scale with dose. The 1 mg group looked close to placebo; the 12 mg group had the highest rates of nausea, vomiting, and stopping treatment. This is why trials use slow titration.

Overall, adverse events of any kind were reported in about 70% of placebo participants and 73-94% of retatrutide participants, with the highest rates in the 8 mg and 12 mg groups (NEJM 2023).

The table below shows approximate gastrointestinal rates by dose from the Phase 2 trial. Treat these as reported ranges, not exact label values, since retatrutide has no FDA label yet.

Adverse event	~1 mg (low)	~8 mg (mid)	~12 mg (high)
Nausea	~14%	rising	up to ~60%
Vomiting	~4%	rising	up to ~25%
Diarrhea	~7%	rising	up to ~23%
Constipation	~5%	rising	up to ~18%
Discontinued for side effects	~6%	—	up to ~16%

For comparison, only about 1% of placebo participants stopped treatment for side effects (NEJM 2023). Investigators also found that a lower starting dose (2 mg instead of 4 mg) cut down on gut symptoms during escalation (Jastreboff et al., PubMed 2023).

Why does dose drive side effects so strongly? The same receptor activity that produces weight loss also slows the gut and signals fullness. Push the dose up and you push both effects. That trade-off is the central tension of the whole drug class.

This is also why titration is not optional. Jumping to a high dose without ramping up is the fastest way to trigger severe nausea and vomiting. The trial built in a slow climb for exactly that reason (NEJM 2023).

The mid-dose column above is marked "rising" because the published figures emphasized the low and high ends. The takeaway holds: rates sit between the 1 mg and 12 mg numbers and climb steadily as dose goes up.

Does retatrutide raise heart rate?

Yes. Retatrutide raised resting heart rate in a dose-related way, by up to about 6.7 beats per minute at the 12 mg dose. The rise peaked near week 24 and then drifted back toward baseline through weeks 36-48 (NEJM 2023).

This matters because it is larger than what is usually seen with the dual and single agonists. Tirzepatide trials reported heart rate increases of roughly 2-4 bpm, and semaglutide around 1-4 bpm (Zepbound label, FDA 2024).

The likely reason is the glucagon arm of the molecule. Glucagon receptor activation pushes up the body's resting energy use, which can nudge heart rate higher.

This is also part of why retatrutide drives such large weight loss. The glucagon component raises energy expenditure on top of the appetite suppression from GLP-1 and GIP. The heart rate effect may be the cost that comes attached to that benefit.

It is worth noting the timing. The increase did not keep climbing. It peaked mid-trial and then eased, which suggests some adaptation over time rather than a steady upward march (NEJM 2023).

Here is the honest part. Phase 2 was not designed or powered to settle whether this heart rate bump causes harm over years. That question is what Phase 3 cardiovascular follow-up is meant to answer. If you have a heart rhythm problem or known cardiovascular disease, this is a conversation to have with your doctor before any trial enrollment.

How do retatrutide's side effects compare to tirzepatide and semaglutide?

All three share the same gut-heavy side effect profile. Retatrutide's standout difference is the larger heart rate increase tied to its glucagon activity. The GI rates are not measured head-to-head in one trial, so cross-trial numbers should be read with caution.

Side effect	Retatrutide (Phase 2, high dose)	Tirzepatide (SURMOUNT-1 / Zepbound)	Semaglutide (STEP 1)
Nausea	up to ~60%	~25-29%	~44%
Vomiting	up to ~25%	~10-13%	~25%
Diarrhea	up to ~23%	~19-23%	~32%
Constipation	up to ~18%	~11-17%	~23%
Any GI event	high, dose-related	~56% across doses	~74%
Heart rate increase	up to ~6.7 bpm	~2-4 bpm	~1-4 bpm
FDA status (2026)	Investigational	Approved (Zepbound)	Approved (Wegovy)

Sources: retatrutide (NEJM 2023); tirzepatide (Zepbound label, FDA 2024); semaglutide (Wilding et al., NEJM 2021).

A key caveat: these came from separate trials with different patient groups, doses, and reporting rules. You cannot read the table as a clean ranking. What it does show is the shared pattern — gut symptoms dominate, and they ease with slow titration (Wilding et al., NEJM 2021).

A few patterns are worth pulling out. Retatrutide's high-dose nausea figure looks higher than the others, but it reflects the top 12 mg arm, not an average across all doses. Average it across the full range and the gap narrows.

Semaglutide's "any GI event" rate of about 74% is striking, but most of those events were mild and transient. High overall rates with low severity is the norm for this class, not a red flag on its own (Wilding et al., NEJM 2021).

The cleanest real difference is heart rate. Retatrutide's roughly 6.7 bpm sits clearly above the 1-4 bpm range for the approved drugs. That is the comparison most worth watching as Phase 3 data arrives (NEJM 2023).

For the full efficacy and trial picture, see our complete retatrutide evidence review.

What serious risks and warnings are known so far?

Retatrutide has no FDA label yet, but it sits in a drug class that carries specific serious warnings. The class concerns below come from approved GLP-1 and dual-agonist labels and are expected to apply.

Thyroid C-cell tumors (boxed warning). Approved drugs in this class carry a boxed warning for thyroid C-cell tumors. It is based on rodent studies showing dose- and duration-related C-cell tumors. The human relevance is unknown, but the warning stands (Zepbound label, FDA 2024).

Pancreatitis. Inflammation of the pancreas has been reported across this class. Severe, persistent stomach pain — sometimes spreading to the back — is the warning sign to act on (Wegovy label, FDA 2023).

Gallbladder problems. Rapid weight loss itself raises gallstone risk, and gallbladder events are noted in class labels (Wegovy label, FDA 2023).

Hypoglycemia. On its own the low-blood-sugar risk is modest. It rises when these drugs are combined with insulin or a sulfonylurea, so doses of those may need lowering (Wegovy label, FDA 2023).

Heart rate. The dose-related heart rate increase covered above is retatrutide's own signal and is still under study in Phase 3 (NEJM 2023).

Diabetic retinopathy. Rapid improvement in blood sugar has been linked to temporary worsening of eye disease in some incretin trials. People with existing retinopathy warrant monitoring (Wegovy label, FDA 2023).

Acute kidney injury. Severe vomiting or diarrhea can cause dehydration, which in turn can stress the kidneys. Staying hydrated and reporting persistent GI symptoms matters (Zepbound label, FDA 2024).

To be clear about the limits here. None of the boxed-warning items has been confirmed as a real human harm from retatrutide specifically. They are class-level cautions carried over from approved drugs, and they will be tested directly in Phase 3.

Who should be cautious or avoid retatrutide in trials?

People with certain thyroid, pancreatic, pregnancy, or cardiac conditions are excluded from or cautioned against these drugs. Below are the contraindications and trial exclusions, broken out.

• Personal or family history of medullary thyroid carcinoma (MTC). This is a hard contraindication for approved drugs in the class (Zepbound label, FDA 2024).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Also a contraindication, because MEN 2 raises MTC risk (Zepbound label, FDA 2024).
• Pregnancy or planning pregnancy. These drugs are not recommended in pregnancy, and weight-loss trials typically exclude pregnant participants (Wegovy label, FDA 2023).
• History of pancreatitis. A prior episode usually warrants caution and may be a trial exclusion.
• Significant heart disease or arrhythmia. Given retatrutide's heart rate effect, people with these conditions need careful evaluation (NEJM 2023).
• Prior severe reaction to a GLP-1 drug. A serious past reaction is a reason to avoid the class.

These overlap with the exclusion criteria used in retatrutide's own trials (NCT04881760). The final list for any approved version will come from the FDA label, if and when one is issued.

Two more groups deserve a flag. People with a history of severe gastrointestinal disease, such as gastroparesis, may tolerate these drugs poorly because the drugs slow the gut further. And anyone with an eating disorder history should approach appetite-suppressing drugs only under close clinical care.

None of this is a do-it-yourself checklist. Retatrutide is investigational, so the only way to take it now is inside a clinical trial with a screening team. For where retatrutide sits among approved options, see our overview of GLP-1 medications and the deeper retatrutide evidence review.

What the evidence does NOT yet establish about long-term safety

The biggest gaps are long-term safety and the meaning of the heart rate signal. Phase 2 ran for 48 weeks. That is short for a drug people may take for years.

We do not yet have large Phase 3 cardiovascular outcome data for retatrutide. So we cannot say whether the heart rate increase changes the risk of heart attack, stroke, or arrhythmia over time (NEJM 2023).

We also lack long-term data on rare events. Thyroid, pancreatic, and gallbladder risks need years and large numbers to measure well. Phase 2 was too small and too short for that (Jastreboff et al., PubMed 2023).

There is no head-to-head trial yet. Every comparison to tirzepatide or semaglutide in this article is cross-trial. A direct, randomized comparison would settle a lot, and none has been published.

We also do not know how the drug behaves in groups left out of Phase 2. Older adults, people with kidney or liver disease, and those on multiple medications were limited or excluded. Their experience may differ (Jastreboff et al., PubMed 2023).

Bottom line: the short-term tolerability story is fairly clear and looks like its class cousins. The long-term safety story is still being written in Phase 3.

Frequently Asked Questions

What is the most common side effect of retatrutide?

Nausea. In the Phase 2 trial it ranged from about 14% at the 1 mg dose up to roughly 60% at the 12 mg dose. Like the other gut symptoms, it was worst during dose escalation and usually mild to moderate (NEJM 2023).

Why does retatrutide increase heart rate?

The leading explanation is its glucagon receptor activity. Glucagon raises resting energy use, which can push heart rate up. In Phase 2, the increase reached about 6.7 bpm at 12 mg, peaked near week 24, then eased back toward baseline (NEJM 2023).

Are retatrutide's side effects worse than Wegovy or Zepbound?

Not clearly. The gut side effects look broadly similar across all three, and cross-trial numbers cannot be ranked precisely. The main difference is retatrutide's larger heart rate increase, about 6.7 bpm versus 1-4 bpm for the others (Wilding et al., NEJM 2021).

Can the side effects be reduced?

In the trial, starting at 2 mg instead of 4 mg lowered gut symptoms during escalation. Slow titration is the standard tool for the whole class. Always follow a doctor's titration plan (Jastreboff et al., PubMed 2023).

Is retatrutide FDA-approved?

No. As of 2026 retatrutide is investigational and in Phase 3 testing. Its full safety profile, including the long-term meaning of the heart rate change, is still being established (NEJM 2023).

Related Reading

• Retatrutide: complete evidence review
• Retatrutide dosage: what the trials used
• CagriSema vs tirzepatide vs retatrutide

-- The GLP-1 Daily Team